Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial.

ABSTRACT:

Objective

To show that limiting dual antiplatelet therapy (DAPT) to six months in patients with event-free ST-elevation myocardial infarction (STEMI) results in a non-inferior clinical outcome versus DAPT for 12 months.

Design

Prospective, randomised, multicentre, non-inferiority trial.

Setting

Patients with STEMI treated with primary percutaneous coronary intervention (PCI) and second generation zotarolimus-eluting stent.

Participants

Patients with STEMI aged 18 to 85 that underwent a primary PCI with the implantation of second generation drug-eluting stents were enrolled in the trial. Patients that were event-free at six months after primary PCI were randomised at this time point.

Interventions

Patients that were taking DAPT and were event-free at six

SUBMITTER: Kedhi E 

PROVIDER: S-EPMC6167608 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature